Developing cutting-edge 

cancer immunotherapy

Next generation cancer immunotherapeutics

Lokon Pharma is a privately owned, cutting-edge pharmaceutical company developing novel cancer immunotherapies for the next generation of cancer therapeutics. Lokon’s proprietary LOAd technology is a family of armed oncolytic viruses that can activate an immune response against the tumor as well as killing tumor cells directly.


LOAd703 oncolytic virus is currently being evaluated in pancreatic cancer, ovarian cancer, colon cancer, biliary cancer and melanoma. Read more about our pipeline and clinical research, LOAd technology, FAQ, and latest news.